Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Dermata Therapeutics Inc WT (NQ: DRMAW )

0.0089 +0.0003 (+3.49%)
Streaming Delayed Price Updated: 11:56 AM EDT, Sep 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Dermata Therapeutics Inc WT

< Previous 1 2 Next >
Dermata Therapeutics Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
SAN DIEGO, CA / ACCESSWIRE / April 21, 2022 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA) and (NASDAQ:DRMAW), a clinical-stage biotechnology company focusing on the treatment... 
From Dermata Therapeutics
Via AccessWire
Dermata Therapeutics Provides Corporate Update and Reports Full Year 2021 Financial Results
DMT310 Phase 2 rosacea trial is over two-thirds enrolled with topline results expected in H2 2022 DMT310 Phase 2 psoriasis trial to start H1 2022, with topline results expected in H1 2023 DMT310 Phase... 
From Dermata Therapeutics
Via AccessWire
Dermata Therapeutics, Inc. Reports Third Quarter 2021 Financial Results and Provides Corporate Update
- Announced positive topline results from DMT310 proof of concept (POC) study in mild-to-moderate psoriasis - - Closed upsized $18.0 million initial public offering (IPO) on Nasdaq Capital Market - -... 
From Dermata Therapeutics
Via AccessWire
Topics Initial Public Offering
Exposures Product Safety Securities Market
Dermata to Present Results from its DMT410 Phase 1b Proof of Concept Aesthetic Study at The American Society for Dermatologic Surgery (ASDS) 2021 Annual Meeting
The presentation will highlight efficacy and safety data from a Phase 1b proof of concept study evaluating one application of DMT410 as a new topical intradermal delivery mechanism of botulinum toxin... 
From Dermata Therapeutics
Via AccessWire
Dermata Therapeutics, Inc. Announces Appointment of Kyri Van Hoose as Senior Vice President, Chief Financial Officer
SAN DIEGO, CA / ACCESSWIRE / September 1, 2021 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA)(NASDAQ:DRMAW), a clinical-stage biopharmaceutical company focused on the... 
From Dermata Therapeutics
Via AccessWire
Dermata Therapeutics, Inc. Announces Closing of Upsized $18.0 Million Initial Public Offering
SAN DIEGO, CA / ACCESSWIRE / August 17, 2021 / Dermata Therapeutics, Inc. ("Dermata" or the "Company") (NASDAQ:DRMA, DRMAW), a clinical-stage medical dermatology company focused on identifying,... 
From Dermata Therapeutics
Via AccessWire
Topics Regulatory Compliance
Exposures Legal Regulatory
Dermata Therapeutics, Inc. Announces Pricing of Upsized $18.0 Million Initial Public Offering
SAN DIEGO, CA / ACCESSWIRE / August 12, 2021 / Dermata Therapeutics, Inc. ("Dermata" or the "Company") (NASDAQ:DRMA)(NASDAQ:DRMAW), a clinical-stage medical dermatology company focused on identifying,... 
From Dermata Therapeutics
Via AccessWire
Topics Regulatory Compliance
Exposures Legal Regulatory
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.